This review concluded that cidofovir or leflunomide addition to immunosuppression reduction therapy for polyomavirus-associated nephropathy management in kidney transplant recipients may not decrease graft failure rate; however, the evidence base was poor and more research is needed. Given this poor evidence base and the risk of bias in the review, the reliability of the authors' cautious conclusions is unclear.
Searching
The reviewers searched MEDLINE and EMBASE (both from inception), and the Cochrane Central Register of Clinical Trials for relevant studies published until October 2008. The search was not restricted to English. Search terms were reported. Bibliographies of previous reviews, eligible trials, and published abstracts from relevant annual meetings (American Transplant Congress meetings, 2005 -2008 were scanned for further relevant studies.
Study selection
Eligible studies were of adults (over 18 years) who developed BK viruria, BK viraemia, or biopsy-proven polyomavirusassociated nephropathy after receiving primary or repeat kidney transplantation. Eligible specified interventions to treat the polyomavirus complications were immunosuppression reduction alone or immunosuppression reduction plus cidofovir, leflunomide, quinolone antibiotic, interferon, or intravenous immunoglobulin. Eligible patients may have received kidney transplantation from a deceased or living donor. No exclusion criteria were reported.
In included studies, methods of screening for BK virus varied substantially and were often not reported. Included studies were conducted in the USA, Europe, Canada, Australia, Korea and Kuwait.
Two reviewers independently screened articles for inclusion. Disagreements were resolved by consensus or arbitration with two other reviewers.
Assessment of study quality
Two reviewers independently assessed study quality using the Jadad scale (blinding, randomisation, withdrawals and dropouts; score between zero and five) for randomised controlled trials (RCTs), or the Newcastle-Ottawa Quality Assessment scale (study group selection, group comparability, ascertainment of exposure/outcome of interest; score between zero and nine) for cohort studies.
Data extraction
Two reviewers independently extracted data required to calculate the primary outcome, graft failure rate, with 95% confidence intervals (CIs); and rates with 95% CIs for a range of secondary outcomes including acute rejection, patient survival and adverse events.
